Lamivudine 300mg + Tenofovir Disoproxil Fumarate 300mg, (equivalent to245mg of Tenofovir Disoproxil), film coated tablets, bottle pack of 30
Indicative Price : Upon Request
NOTE: The description below is for a standard product. It is not specific to patent status and pricing policies that may apply at country level. This information is available on request from Supply Division: Contact: email@example.com
Lamivudine 300mg + Tenofovir Disoproxil Fumarate 300mg, equivalent to 245mg of Tenofovir Disoproxil, film coated tablets, bottle pack of 30
Each film coated tablet contains Lamivudine 300mg and Tenofovir Disoproxil fumarate 300mg which is equivalent to 245mg of Tenofovir Disoproxil.
Lamivudine is a Nucleoside Reverse Transcriptase Inhibitor (NRTI)
Tenofovir is a Nucleotide Reverse Transcriptase Inhibitor (NtRTI)
Standard shelf life:
2 years (24 months)
Other available formulations:
The product may also be available in other formulations, pack sizes, or in combinations with other ARVs.
Guidelines for use:
For more details, please click the links listed below:
WHO treatment guidelines
WHO Essential Medicines Library
or your regional national guidelines
For details about paediatric dosage schemes, please click the links listed below:
WHO Generic tool for assessing paediatric ARV dosing
Management of HIV-1 infection in adults in combination with at least two other antiretroviral drugs. By mouth (oral), PO
Store at 25ºC (77ºF) in a tightly closed original container. Excursions permitted to 15-30ºC (59-86ºF).
Keep out of reach and sight of children.
Dispense in original container. Do not repack
To be taken without regard to food
For latest updates, please click the links listed below:
List of WHO Prequalified Medicines
List of USFDA approved and tentatively approved items
|To see icon descriptions, go to |
' Product attribute guide'